Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Genomic Landscape Impacts Induction Outcome with CPX-351 in Patients with Acute Myeloid Leukemia

Chetasi Talati, MD, Aaron D Goldberg, MD PhD, Pinkal Desai, MD MPH, Onyee Chan, MD, Christopher Famulare, MS, Rami S. Komrokji, MD, Andrew T Kuykendall, MD, Hugo F. Fernandez, MD, Yehuda E. Deutsch, MD, Eric Padron, MD, Alan F. List, MD, Jeffrey E. Lancet, MD, Gail J. Roboz, MD, Martin S. Tallman, MD, David A Sallman, MD, Kendra L. Sweet, MD

Blood (2018) 132 (Supplement 1): 2741.

https://doi.org/10.1182/blood-2018-99-117412

Published: 2018

Journal Articles

Acute Myeloid Leukemia (AML) with Somatic Mutations in PTPN11 Is Associated with Treatment Resistance and Poor Overall Survival

Justin D. Kaner, MD, Nuria Mencia-Trinchant, PhD, Ariel Schaap, MD, Gail J. Roboz, MD, Sangmin Lee, MD, Pinkal Desai, MD MPH, Michael Samuel, MD, Spencer Krichevsky, BS, Idongessit Udoyen, Duane C. Hassane, PhD, Monica L. Guzman, PhD, Ellen K. Ritchie, MD

Blood (2018) 132 (Supplement 1): 2760.

https://doi.org/10.1182/blood-2018-99-110319

Published: 2018

Journal Articles

Correlations between Pre-Transplant Treatment and Bone Marrow Response with Post-Transplant Outcomes in Patients with Myelodysplastic Syndrome Undergoing Allogeneic Stem Cell Transplantation

Pinkal Desai, MD MPH, Alfadel Alshaibani, MD, Xian Wu, MPH, Sangmin Lee, MD, Jingmei Hsu, MD, Ellen K. Ritchie, MD, Michael Samuel, MD, Sebastian A. Mayer, MD, Adrienne A. Phillips, MD MPH, Usama Gergis, MD M.B.A, Tsiporah B. Shore, MD, Koen Van Besien, MD PhD, Gail J. Roboz, MD

Blood (2018) 132 (Supplement 1): 4391.

https://doi.org/10.1182/blood-2018-99-118366

Published: 2018

Journal Articles

TP53 Mutations Predict Poorer Responses to CPX-351 in Acute Myeloid Leukemia

Aaron D Goldberg, MD PhD, Chetasi Talati, MD, Pinkal Desai, MD MPH, Christopher Famulare, MS, Sean M Devlin, PhD, Noushin Farnoud, PhD, David A Sallman, MD, Jeffrey E. Lancet, MD, Gail J. Roboz, MD, Kendra L. Sweet, MD, Martin S. Tallman, MD

Blood (2018) 132 (Supplement 1): 1433.

https://doi.org/10.1182/blood-2018-99-117772

Published: 2018

Journal Articles

Does Presence of Persistent Molecular Mutations Matter in AML Patients Undergoing Allogeneic Stem Cell Transplant?

Sangmin Lee, MD, Jingmei Hsu, MD, Yassine Tahri, MD, Zhengming Chen, PhD MPH, MS, Tsiporah B. Shore, MD, Ellen K. Ritchie, MD, Usama Gergis, MD M.B.A, Pinkal Desai, MD MPH, Sebastian A. Mayer, MD, Michael Samuel, MD, Adrienne A. Phillips, MD MPH, Melissa M. Cushing, MD, Gail J. Roboz, MD, Koen Van Besien, MD PhD

Blood (2018) 132 (Supplement 1): 2172.

https://doi.org/10.1182/blood-2018-99-119946

Published: 2018

Journal Articles

Incidence of Infections and Second Cancers in Philadelphia Chromosome-Negative Patients with Myeloproliferative Neoplasms Treated with Ruxolitinib

Ellen K Ritchie, MD, Spencer Krichevsky, BS, Gail J. Roboz, MD, Richard T Silver, MD, Andrew I Schafer, MD, Joseph Scandura, MDPhD, Pinkal Desai, MD MPH, Sangmin Lee, MD, Michael Samuel, MD

Blood (2017) 130 (Supplement 1): 2910.

https://doi.org/10.1182/blood.V130.Suppl_1.2910.2910

Published: 2017

Journal Articles

Is Serial Monitoring of Myeloid Mutations Clinically Relevant in Myelodysplastic Syndromes (MDS): A Report on Behalf of the MDS Clinical Research Consortium (CRC)

Sangmin Lee, MD, John Barnard, PhD, Amy E. DeZern, MD MHS, Jaroslaw P Maciejewski, MD PhD FACP, Najla Alali, MS, David P. Steensma, MD, Ellen K. Ritchie, MD, Pinkal Desai, MD, Guillermo Garcia-Manero, MD, Fatima Ali, B.S., Nicole Rizzo, BA, Duane C Hassane, PhD, Rami S. Komrokji, MD, Mikkael A. Sekeres, MD MS, Gail J. Roboz

Blood (2016) 128 (22): 297.

https://doi.org/10.1182/blood.V128.22.297.297

Published: 2016

Journal Articles

Arterial Thrombotic Complications Are Uncommon in Patients without Cardiovascular Risk Factors and Occur at Equivalent Rates in Chronic Myeloid Leukemia (CML) Patients Treated with Imatinib and Nilotinib

Hesam Hekmatjou, MD, Gail J. Roboz, MD, Ellen K. Ritchie, MD, Sangmin Lee, MD, Pinkal Desai, MD, Joseph M. Scandura, MD PhD, Sandra Allen-Bard, ANP, BS, BSN, MSN, NP, Paul Christos, DrPH, Richard T. Silver, MD, Eric J. Feldman, MD

Blood (2014) 124 (21): 1811.

https://doi.org/10.1182/blood.V124.21.1811.1811

Published: 2014

NARROW

Genomic Landscape Impacts Induction Outcome with CPX-351 in Patients with Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML) with Somatic Mutations in PTPN11 Is Associated with Treatment Resistance and Poor Overall Survival

Correlations between Pre-Transplant Treatment and Bone Marrow Response with Post-Transplant Outcomes in Patients with Myelodysplastic Syndrome Undergoing Allogeneic Stem Cell Transplantation

TP53 Mutations Predict Poorer Responses to CPX-351 in Acute Myeloid Leukemia

Does Presence of Persistent Molecular Mutations Matter in AML Patients Undergoing Allogeneic Stem Cell Transplant?

Incidence of Infections and Second Cancers in Philadelphia Chromosome-Negative Patients with Myeloproliferative Neoplasms Treated with Ruxolitinib

Is Serial Monitoring of Myeloid Mutations Clinically Relevant in Myelodysplastic Syndromes (MDS): A Report on Behalf of the MDS Clinical Research Consortium (CRC)

Arterial Thrombotic Complications Are Uncommon in Patients without Cardiovascular Risk Factors and Occur at Equivalent Rates in Chronic Myeloid Leukemia (CML) Patients Treated with Imatinib and Nilotinib

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only